Epilepsy

Preliminary Pre-Clinical Evaluation of a Molecule With Anti-Seizure Effects

BICS01 Epilepsy ASD molecule

Despite the availability of around 30 anti-seizure drugs, drug-resistant epilepsy remains a significant clinical and societal burden. We report the first promising result of a new candidate BICS01.

Planegg / Martinsried (Germany) – January 7, 2022 – Bicoll, an expert in synthesizing new and relevant small molecules as starting points for accelerated drug development, worked together with its partners at the University College London, FutureNeuro, and Royal College of Surgeons to publish data for a promising anti-seizure drug candidate BICS01 in Frontiers in Neurology.

Read more

EpimiRNA: 5 years of successful work to reduce the seizures

5 years of collaborative work with 16 partners under the 7th Framework Programme have been finished with the great results and desire to work further on epilepsy. Bicoll small molecule appeared to be reducing the epileptic seizures and miRNA can …

Read more

EpimiRNA: Third General Assembly

Dr. Kai Lamottke presents the results on the topic “New miRNA-Modulating Chemical Entities for the Treatment of Epilepsy” as a workpackage leader of EU-project during the 3rd General Assembly of EpimiRNA. Read more from the project coordinator David Henshall of …

Read more

Join us at Biotechgate Partnering February 7th - 11thBiotechgate Partnering
+ +